Our People

Co-founder, Chairman & CEO

• Over 15 years of experience in the field of biopharmaceutical analysis; had extensive expertise in team management and the development, validation and transfer of biologics analytical methods. Worked at Calibrant Biosystems, Bristol Myers Squibb (BMS), and WuXi Biologics. Obtained a M.S. in Biochemistry from Xiamen University, China and a Ph.D. degree in Bioanalytical Chemistry from the University of Maryland, USA
  

• Expertise:  Analytical studies, including stability, characterization, and comparability studies, method development and transfer, CMC support and regulatory compliance

Co-founder, VP of Business Development

• 26 years of experience in pharmaceutical development, including 14 years at Merck with various leadership positions. Headed the API group - Center for Materials Science and Engineering in Merck Manufacturing Division. Established the first analytical research group in Ireland for Merck, while also maintaining direct responsibilities for overseeing the solid-state NMR facility. Obtained a Ph.D. degree in Chemistry from Pennsylvania State University

• Expertise: Solid-state NMR, drug characterization, crystallization development, IP protection; Expert witness on crystal form patent cases

CFO & Secretary of the Board, Head of the CRO BU NJ Site

• With more than 20 years of financial management experience and rich overseas practical experience. Qualified ACCA Member since 2008. Obtained a master’s degree in management from Tsinghua University

COO, Head of the CRO BU SZ Site

• With over 14 years of experience in business management. Worked as Vice President of Finance at Xiaodu Technology, a subsidiary company of Baidu Group; served as Sr. Investment Director at Baidu Group. Worked for Standard Chartered Group and a couple of other well-known investment corporations in the past. Obtained a Master degree of Business Administration from Renmin University of China

Head of US Business Development - CRO & CDMO BU

• With over 25 years of senior business development experience in servicing the pharmaceutical and biotechnology industry. Worked as the Director of Global Sales and Custom Solutions at ATCC; the Global Director for the Health Sciences Division at NSF; the Vice President of Business Development, Marketing, and Global Distribution for Associates of Cape Cod; the Senior Director of Commercial Development at Tripos Inc.

• Held several positions of increasing responsibility in sales & marketing management with IGEN International, Corning Corporation, Costar Corporation and Genetics Institute. As a Stockbroker and Portfolio Manager with Prudential Bache Securities for 3 years. Obtained a B.S. in Biology from Western New England University

Executive Director & Head of Small Molecule Division - NJ Site

• 15 years of working experience in Merck with various leadership positions including Leader of API Development Support Group - Center for Materials Science and Engineering in Merck Manufacturing Division, and Analytical Project Leader - Merck Animal Health. Obtained Ph.D. in Materials Science, Georgetown University (Studied chiral separation and crystallization in gels under Professor Jennifer Swift, Ph.D.)

• Expertise: API solid form screening/discovery, crystalline form selection, polymorphism, and chiral separations by crystallization

Head of R&D – CRO Business Unit, China

• 7 years of solid-state research and pre-formulation development experience. Led a team to support solid-state research and crystallization for more than 200 compounds and supported the IND filing. Obtained a B.E. and a Ph.D. degree in chemistry from Tsinghua University

• Expertise: API solid-state research, crystallization development, and pre-formulation research

CEO - CDMO Business Unit, China

• 22 years of formulation development and CRO/CDMO/CMO vendor management experience at Merck (US) and MSD (China). Expertise on oral solid formulation development, analytical and clinical supply. Responsible for or supported over 30 new drug development, 5 of which were commercialized. Trained as Chemical Engineer at Lehigh Univ. (Ph.D.) and Tsinghua Univ. (BS)

• Expertise: Oral solid formulation development, analytical and clinical supply

CSO - CDMO Business Unit, China

• 21 years of Phase I-III and commercial formulation development experience at Merck (US). Involved in over 50 small molecule NCE drug product development, 15 of which were commercialized. Significant expertise on oral solid dosage, powder mechanics, dry granulation and pediatric formulation. Trained as an engineer (mechanical leaning) at Penn State Univ. (Ph.D.) and China Agricultural Univ. (BE)

• Expertise: Oral solid dosage, preclinical formulation powder mechanics, dry granulation, high shear wet granulation (HSWG) and pediatric formulation

CTO - CDMO Business Unit, China

• 18 years of pre-formulation, formulation (preclinical-III) and process development, regulatory filing and product commercialization experience at Roche, Abbott, Merck, Sunovion and Sage Therapeutics. Involved in over 35 early phase and 7 commercial products development. Skilled in various delivery systems and unit operations. Trained as Chemical Engineer (Ph.D., Univ. of Texas at Austin; BS and MS, Tsinghua University) and Pharmacometrics (MS, Univ. of Maryland at Baltimore)

• Expertise: Various delivery systems, preclinical formulation, formulation development, manufacturing unit operations and scale up

CEO - CDMO Business Unit, Canada

• 17 years of formulation development and management experience in innovative and generic pharmaceutical industries. Developed more than 30 products for global markets including First-to-Files, NCE, 505 b (2) and First-to-Markets. Ph.D. degree in Pharmaceutics and Drug Delivery from Faculty of Pharmacy, University of Toronto, Canada

• Expertise: Complex oral delivery systems, solubility/permeability enhancement, peptide delivery, bioequivalence, and alignment of nonclinical and clinical formulations for NCE drugs